Home>>Signaling Pathways>> Apoptosis>>SJ6986

SJ6986 Sale

目录号 : GC62318

A degrader of GSPT1 and GSPT2

SJ6986 Chemical Structure

Cas No.:2765625-93-0

规格 价格 库存 购买数量
5 mg
¥540.00
现货
10 mg
¥855.00
现货
25 mg
¥1,710.00
现货
50 mg
¥2,790.00
现货
100 mg
¥4,410.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

SJ6986 is a degrader of G1 to S phase transition 1 (GSPT1) and GSPT2.1 It reduces the levels of GSPT1 and GSPT2 in MV4-11 cells in a concentration-dependent manner. SJ6986 inhibits proliferation of MV4-11, MHH-CALL-4, MB002, MB004, and HD-MB03 cells (EC50s = 1.5, 0.4, 726, 336, and 3,583 nM, respectively) and reduces the viability of MV4-11 cells endogenously expressing cereblon but not MV4-11 cereblon knockout cells.

1.Nishiguchi, G., Keramatnia, F., Min, J., et al.Identification of potent, selective, and orally bioavailable small-molecule GSPT1/2 degraders from a focused library of cereblon modulatorsJ. Med. Chem.64(11)7296-7311(2021)

Chemical Properties

Cas No. 2765625-93-0 SDF
分子式 C20H14F3N3O7S 分子量 497.4
溶解度 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.0105 mL 10.0523 mL 20.1045 mL
5 mM 0.4021 mL 2.0105 mL 4.0209 mL
10 mM 0.201 mL 1.0052 mL 2.0105 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators

J Med Chem 2021 Jun 10;64(11):7296-7311.PMID:34042448DOI:PMC8201443

Whereas the PROTAC approach to target protein degradation greatly benefits from rational design, the discovery of small-molecule degraders relies mostly on phenotypic screening and retrospective target identification efforts. Here, we describe the design, synthesis, and screening of a large diverse library of thalidomide analogues against a panel of patient-derived leukemia and medulloblastoma cell lines. These efforts led to the discovery of potent and novel GSPT1/2 degraders displaying selectivity over classical IMiD neosubstrates, such as IKZF1/3, and high oral bioavailability in mice. Taken together, this study offers compound 6 (SJ6986) as a valuable chemical probe for studying the role of GSPT1/2 in vitro and in vivo, and it supports the utility of a diverse library of CRBN binders in the pursuit of targeting undruggable oncoproteins.